These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29567461)

  • 1. PrEP-001 prophylactic effect against rhinovirus and influenza virus - RESULTS of 2 randomized trials.
    Malcolm BA; Aerts CA; Dubois KJ; Geurts FJ; Marien K; Rusch S; Van Dijck AH; Verloes R; Vingerhoets J
    Antiviral Res; 2018 May; 153():70-77. PubMed ID: 29567461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged Primary Rhinovirus Infection of Human Nasal Epithelial Cells Diminishes the Viral Load of Secondary Influenza H3N2 Infection via the Antiviral State Mediated by RIG-I and Interferon-Stimulated Genes.
    Ong HH; Liu J; Oo Y; Thong M; Wang Y; Chow VT
    Cells; 2023 Apr; 12(8):. PubMed ID: 37190061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial.
    Turner RB; Wecker MT; Pohl G; Witek TJ; McNally E; St George R; Winther B; Hayden FG
    JAMA; 1999 May; 281(19):1797-804. PubMed ID: 10340366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.
    Rudenko L; Kiseleva I; Stukova M; Erofeeva M; Naykhin A; Donina S; Larionova N; Pisareva M; Krivitskaya V; Flores J;
    Vaccine; 2015 Sep; 33(39):5110-7. PubMed ID: 26296497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model.
    McBride JM; Lim JJ; Burgess T; Deng R; Derby MA; Maia M; Horn P; Siddiqui O; Sheinson D; Chen-Harris H; Newton EM; Fillos D; Nazzal D; Rosenberger CM; Ohlson MB; Lambkin-Williams R; Fathi H; Harris JM; Tavel JA
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1.
    Mössler C; Groiss F; Wolzt M; Wolschek M; Seipelt J; Muster T
    Vaccine; 2013 Dec; 31(52):6194-200. PubMed ID: 24183981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections.
    Mukherjee PK; Esper F; Buchheit K; Arters K; Adkins I; Ghannoum MA; Salata RA
    BMC Infect Dis; 2017 Jan; 17(1):74. PubMed ID: 28088167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans.
    Pleguezuelos O; Robinson S; Fernández A; Stoloff GA; Mann A; Gilbert A; Balaratnam G; Wilkinson T; Lambkin-Williams R; Oxford J; Caparrós-Wanderley W
    Clin Vaccine Immunol; 2015 Jul; 22(7):828-35. PubMed ID: 25994549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of probiotic on innate inflammatory response and viral shedding in experimental rhinovirus infection - a randomised controlled trial.
    Turner RB; Woodfolk JA; Borish L; Steinke JW; Patrie JT; Muehling LM; Lahtinen S; Lehtinen MJ
    Benef Microbes; 2017 Apr; 8(2):207-215. PubMed ID: 28343401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study.
    Stevens M; Rusch S; DeVincenzo J; Kim YI; Harrison L; Meals EA; Boyers A; Fok-Seang J; Huntjens D; Lounis N; Mari N K; Remmerie B; Roymans D; Koul A; Verloes R
    J Infect Dis; 2018 Jul; 218(5):748-756. PubMed ID: 29684148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study.
    Hershberger E; Sloan S; Narayan K; Hay CA; Smith P; Engler F; Jeeninga R; Smits S; Trevejo J; Shriver Z; Oldach D
    EBioMedicine; 2019 Feb; 40():574-582. PubMed ID: 30638863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progesterone-Based Contraceptives Reduce Adaptive Immune Responses and Protection against Sequential Influenza A Virus Infections.
    Hall OJ; Nachbagauer R; Vermillion MS; Fink AL; Phuong V; Krammer F; Klein SL
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28179523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of glucocorticoid prophylaxis against experimental rhinovirus infection.
    Farr BM; Gwaltney JM; Hendley JO; Hayden FG; Naclerio RM; McBride T; Doyle WJ; Sorrentino JV; Riker DK; Proud D
    J Infect Dis; 1990 Nov; 162(5):1173-7. PubMed ID: 2172395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza.
    Ramos EL; Mitcham JL; Koller TD; Bonavia A; Usner DW; Balaratnam G; Fredlund P; Swiderek KM
    J Infect Dis; 2015 Apr; 211(7):1038-44. PubMed ID: 25281755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.
    Hung IF; Zhang AJ; To KK; Chan JF; Li P; Wong TL; Zhang R; Chan TC; Chan BC; Wai HH; Chan LW; Fong HP; Hui RK; Kong KL; Leung AC; Ngan AH; Tsang LW; Yeung AP; Yiu GC; Yung W; Lau JY; Chen H; Chan KH; Yuen KY
    Lancet Infect Dis; 2016 Feb; 16(2):209-18. PubMed ID: 26559482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza.
    Hayden FG; Treanor JJ; Betts RF; Lobo M; Esinhart JD; Hussey EK
    JAMA; 1996 Jan 24-31; 275(4):295-9. PubMed ID: 8544269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigenic Drift of A/H3N2/Virus and Circulation of Influenza-Like Viruses During the 2014/2015 Influenza Season in Poland.
    Bednarska K; Hallmann-Szelińska E; Kondratiuk K; Brydak LB
    Adv Exp Med Biol; 2016; 905():33-8. PubMed ID: 26956457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers.
    Hayden FG; Turner RB; Gwaltney JM; Chi-Burris K; Gersten M; Hsyu P; Patick AK; Smith GJ; Zalman LS
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3907-16. PubMed ID: 14638501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.